Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2011 2
2012 2
2014 4
2015 6
2016 6
2017 5
2018 2
2019 3
2020 4
2021 2
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, Wang YC, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, Yang L. Li YR, et al. Among authors: zhu y. Cell Rep Med. 2021 Nov 16;2(11):100449. doi: 10.1016/j.xcrm.2021.100449. eCollection 2021 Nov 16. Cell Rep Med. 2021. PMID: 34841295 Free PMC article.
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J. Carey LA, et al. Among authors: zhu y. NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5. NPJ Breast Cancer. 2022. PMID: 35680967 Free PMC article.
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Alkhouri N, et al. Among authors: zhu y. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. J Hepatol. 2022. PMID: 35439567 Free article. Clinical Trial.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. O'Shaughnessy J, et al. Among authors: zhu y. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35545724 Free PMC article. Clinical Trial.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3 and STELLAR-4 Investigators. Harrison SA, et al. Among authors: zhu y. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy.
Siegler EL, Zhu Y, Wang P, Yang L. Siegler EL, et al. Among authors: zhu y. Cell Stem Cell. 2018 Aug 2;23(2):160-161. doi: 10.1016/j.stem.2018.07.007. Cell Stem Cell. 2018. PMID: 30075127 Free article.
44 results